StockData
Autonomix Medical, Inc. logo

Autonomix Medical, Inc. (AMIX) company profile

AMIXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.08−0.02 (-1.82%)

Close on Nov 17, 2026Market cap $1.05MP/E –Yield –

About Autonomix Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

Autonomix Medical is a development-stage medical device enterprise focused on advancing diagnostic and therapeutic technologies for nervous system disorders. The company develops a catheter-based platform that combines high-sensitivity neural signal detection with targeted radiofrequency ablation, utilizing a "sense, treat, verify" approach to improve procedural precision. Its primary offerings comprise a proprietary microchip-enabled sensing catheter, an RF ablation catheter, a dedicated RF generator, and visualization software. Designed to navigate transvascular pathways, these systems target peripheral nerve fibers initially to manage pain associated with pancreatic cancer. The technology is tailored for interventional radiologists and cardiologists operating in hospital catheter laboratories, with potential future applications covering additional visceral pain conditions, hypertension, and other nerve-related disorders.

The company operates without commercial facilities or retail locations, functioning through prototype development, third-party manufacturing partnerships, and clinical trial sites. It maintains an international intellectual property portfolio covering technologies across the United States, Europe, Canada, Australia, China, India, Japan, Mexico, and Singapore. The provided report does not state the specific location of its corporate headquarters.

Summary of the business section of Autonomix Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Autonomix Medical, Inc.
Headquarters
The Woodlands, TX
Address
21 Waterway Avenue, Suite 300 77380
Phone
(832) 277-7816
Employees
11, Mar 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
March 31
Auditor
ForvisMazars,LLP, Atlanta, Georgia

Stock & identifiers

Ticker
AMIX
Exchange
Nasdaq
IPO date
Jan 29, 2024
Shares outstanding
1M, Aug 6, 2026
Public float
$6.31M, Sep 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-21 reverse, Jun 24, 2026; 1-for-13.5 reverse, Nov 8, 2024; 1-for-20 reverse, Oct 25, 2024
SEC CIK
1617867
CUSIP
05330T304
ISIN
US05330T3041
FIGI
BBG00R28GXW5
Share class FIGI
BBG00R28GXX4
EIN
47-1607810

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Trent N. SmithCFO15,119
Bradley HauserCEO and President27,000
Sandra C. KalterDirector–
Lori BissonDirector13,119
Walter V. KlempDirector20,118
Christopher CapelliDirector–

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryIncentive payTotalvs. prior year
Brad Hauser
Chief Executive Officer and President
$468.00K$202.18K$670.18K-60%
Lori Bisson
Executive Vice Chairman
$150.00K$54.00K$204.00K-69%
Trent Smith
Chief Financial Officer
$296.40K$85.36K$381.76K-38%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 25, 2024
Offer price
$6.54
Securities offered
458,691
Gross proceeds
$3.00M
Exchange
Nasdaq
Lock-up ends (est.)
May 24, 2025

“Per Common Stock Unit Per PFW Unit Total Public offering price $ 6.5400 $ 6.53900 $ 8,999,999.38 Underwriting discounts and commissions (1) $ 0.5232 $ 0.52312 $ 719,999.95 Proceeds, before expenses, to us (2) $ 6.0168 $ 6.01588 $ 8,279,999.43 (1) Represents underwriting discounts equal to 8% per Common Stock Unit or PFW Unit, as applicable”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 31, 2025, we have 11 employees providing services to the Company, eight on a full-time basis and three on a part-time basis.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?